ArticleFrontiers in oncology2026
Correlation of quantitative background parenchymal enhancement with prognostic factors in breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To semi-automatically quantify background parenchymal enhancement (BPE) in the contralateral healthy breast of patients with unilateral invasive breast cancer and investigate its correlation with prognostic factors, aiming to provide an imaging-based basis for breast cancer prognostic assessment. Materials and methods: A retrospective analysis was conducted on 124 patients with pathologically confirmed unilateral invasive breast cancer treated at Shenzhen Longgang Central Hospital between January 2019 and December 2024, BPE in the unaffected breast was quantified semi-automatically from DCE-MRI (phase 2 post-contrast) using 3D Slicer software (v5.6.2). Associations between quantitative BPE and prognostic factors (menopausal status, axillary lymph node metastasis, BMI, molecular subtype [Luminal A, Luminal B, HER-2+, triple-negative], ER, PR, HER-2, Ki-67) and systemic biomarkers (age, NLR, LMR, SII) were assessed using Mann-Whitney U, Kruskal-Wallis H, and Spearman's correlation tests. Results: Quantitative BPE showed no significant differences based on menopausal status, axillary lymph node status, ER/PR/HER-2 status, BMI category, or molecular subtype (all Conclusion: Our study found that quantitative background parenchymal enhancement (BPE) was significantly lower in the Ki-67 high-expression group than in the low-expression group, suggesting a negative association with tumor proliferative activity. In addition, a certain correlation was also observed between BPE and the systemic inflammatory marker PLR. These findings provide preliminary clues for exploring BPE as an adjunctive imaging biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.